title: The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?
abstract: BACKGROUND
  Recent studies have suggested that the salutary actions of clozapine in schizophrenia may be due to selective activation of M(1) muscarinic receptors by clozapine and/or its major active metabolite N-desmethylclozapine.
  
  
  OBJECTIVE
  We systematically tested this hypothesis by screening a large number of psychoactive compounds, including many atypical antipsychotic drugs, for agonist activity at cloned, human M(1), M(3) and M(5) muscarinic receptors.
  
  
  RESULTS
  Only three of the 14 atypical antipsychotic drugs we tested were found to possess partial agonist actions at M(1) muscarinic receptors (fluperlapine, JL13, clozapine). A few additional miscellaneous compounds had a modest degree of M(1) agonist actions. Only carbachol and N-desmethylclozapine had appreciable M(3) muscarinic agonism at M(3) muscarinic receptors, although several were M(5) partial agonists including MK-212, N-desmethylclozapine and xanomeline.
  
  
  CONCLUSIONS
  Although M(1) muscarinic receptor-selective partial agonists have shown promise in some preclinical antipsychotic drug models, these studies indicate that it is unlikely that the salutary actions of clozapine and similar atypical antipsychotic drugs are mediated solely by M(1) muscarinic receptor activation. It is possible, however, that the M(1) agonism of N-desmethylclozapine contributes to the uniquely beneficial actions of clozapine. Thus, these results are consistent with the notion that a balanced degree of activity at multiple biogenic amine receptors, including M(1) muscarinic agonism, is responsible for the uniquely beneficial actions of clozapine.
authors.affiliation: Department of Psychiatry, Case Western Reserve University Medical School, Cleveland, OH 44106, USA.
authors.forename: Marilyn A
authors.initials: MA
authors.lastname: Davies
authors.forename: Beth Ann
authors.initials: BA
authors.lastname: Compton-Toth
authors.forename: Sandra J
authors.initials: SJ
authors.lastname: Hufeisen
authors.forename: Herbert Y
authors.initials: HY
authors.lastname: Meltzer
authors.forename: Bryan L
authors.initials: BL
authors.lastname: Roth
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000145:classification / Q000494:pharmacology; D016466:CHO Cells; D003024:Clozapine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006224:Cricetinae; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D011600:Psychopharmacology / Q000379:methods; D011725:Pyridines / Q000494:pharmacology; D011976:Receptors, Muscarinic / Q000145:classification* / Q000187:drug effects* / Q000235:genetics; D013830:Thiadiazoles / Q000494:pharmacology
chemical_list: D014150:Antipsychotic Agents; D011725:Pyridines; D011976:Receptors, Muscarinic; D013830:Thiadiazoles; C058272:norclozapine; C075257:xanomeline; D003024:Clozapine